TREX-1-Related Disease Associated with the Presence of Cryofibrinogenemia.


Journal

Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137

Informations de publication

Date de publication:
01 2019
Historique:
received: 28 09 2018
accepted: 17 12 2018
pubmed: 28 1 2019
medline: 27 11 2019
entrez: 28 1 2019
Statut: ppublish

Résumé

Cryofibrinogenemia is a rare cryopathy presenting as acrocyanosis following exposure to cold. Familial presentation has been described but the underlying molecular cause remained undetermined. Forty (40) members from a large family with an initial diagnosis of familial cryofibrinogenemia were interviewed and examined to determine affected status and collect DNA. Exome sequencing was performed on three affected individuals from distinct branches of the pedigree. Seventeen (17) family members reported a history of acrocyanosis with cold exposure. None reported symptoms were suggestive of lupus. Exome sequencing of three subjects identified the heterozygous mutation D18N in the TREX1 gene which was then confirmed by Sanger sequencing in all affected as well as 2 unaffected family members. The mutation is already being associated with familial chilblain lupus erythematosus (CHLE), and a systematic review of literature was undertaken to compare reports of familial CHLE and cryofibrinogenemia. Both entities were found to share highly similar clinical presentations suggesting they are part of a same syndrome in which cryofibrinogenemia and lupus manifestations have variable penetrance. Familial cryofibrinogenemia without lupus should be added to the spectrum of TREX1-related disease.

Identifiants

pubmed: 30685859
doi: 10.1007/s10875-018-0584-x
pii: 10.1007/s10875-018-0584-x
doi:

Substances chimiques

Phosphoproteins 0
DNA 9007-49-2
Exodeoxyribonucleases EC 3.1.-
three prime repair exonuclease 1 EC 3.1.16.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

118-125

Références

Nat Immunol. 2014 May;15(5):415-22
pubmed: 24747712
Clin Rheumatol. 2008 Oct;27(10):1341
pubmed: 19125230
Br J Dermatol. 2012 Jul;167(1):212-4
pubmed: 22356656
J Clin Rheumatol. 2013 Apr;19(3):142-8
pubmed: 23519183
Rheumatology (Oxford). 2008 Feb;47(2):205-7
pubmed: 18208822
J Med Genet. 1989 Oct;26(10):631-6
pubmed: 2585459
JAMA Dermatol. 2015 Apr;151(4):426-31
pubmed: 25517357
J Neurol. 2013 Oct;260(10):2653-5
pubmed: 23989343
Clin Exp Immunol. 2000 May;120(2):253-60
pubmed: 10792373
Exp Dermatol. 2008 Jul;17(7):553-68
pubmed: 18558993
Eur J Med Genet. 2017 Dec;60(12):690-694
pubmed: 28919362
J Mol Med (Berl). 2007 May;85(5):531-7
pubmed: 17440703
Ann Neurol. 1984 Jan;15(1):49-54
pubmed: 6712192
J Clin Immunol. 2015 Apr;35(3):235-43
pubmed: 25731743
J Am Acad Dermatol. 2013 Oct;69(4):e179-81
pubmed: 24034389
Br J Rheumatol. 1996 Jan;35(1):102-4
pubmed: 8624616
Rheumatology (Oxford). 2013 Feb;52(2):406-8
pubmed: 22829693
Am J Med Genet A. 2010 Oct;152A(10):2612-7
pubmed: 20799324
J Invest Dermatol. 2012 Dec;132(12):2855-7
pubmed: 22718116
Proc Natl Acad Sci U S A. 2015 Apr 21;112(16):5117-22
pubmed: 25848017
Rheumatology (Oxford). 2017 Sep 1;56(9):1445-1451
pubmed: 27789759
J Biol Chem. 2011 Sep 16;286(37):32373-82
pubmed: 21808053
Hum Mol Genet. 2016 Jan 15;25(2):358-70
pubmed: 26561523
J Biol Chem. 1993 Mar 15;268(8):5879-85
pubmed: 7680650
Am J Med. 2009 Dec;122(12):1128-35
pubmed: 19958891
J Biol Chem. 2007 Apr 6;282(14):10537-43
pubmed: 17293595
J Eur Acad Dermatol Venereol. 1999 Jan;12(1):47-50
pubmed: 10188150

Auteurs

C Paradis (C)

CHUM Research Center, Université de Montréal, Montreal, Canada.

M Cadieux-Dion (M)

CHUM Research Center, Université de Montréal, Montreal, Canada.
Center for Pediatric Genomic Medicine, Children's Mercy Hospital, Kansas City, MO, USA.

C Meloche (C)

CHUM Research Center, Université de Montréal, Montreal, Canada.

M Gravel (M)

CHUM Research Center, Université de Montréal, Montreal, Canada.

J Paradis (J)

Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, Canada.

A Des Roches (A)

Department of Pediatrics, Centre Hospitalier Universitaire Ste-Justine, Montréal, Canada.

G Leclerc (G)

Department of Medicine, Chicoutimi Hospital, Saguenay, Canada.

P Cossette (P)

CHUM Research Center, Université de Montréal, Montreal, Canada.
Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, Canada.

P Begin (P)

CHUM Research Center, Université de Montréal, Montreal, Canada. philippe.begin@umontreal.ca.
Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, Canada. philippe.begin@umontreal.ca.
Department of Pediatrics, Centre Hospitalier Universitaire Ste-Justine, Montréal, Canada. philippe.begin@umontreal.ca.
Department of Medicine, Chicoutimi Hospital, Saguenay, Canada. philippe.begin@umontreal.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH